image: An FDA-approved HDAC inhibitor named SAHA reduced the size of heart cells and the thickness of ventricular walls in a new cat model of heart failure (right, compared to control in middle). This material relates to a paper that appeared in the Jan. 8, 2020, issue of Science Translational Medicine, published by AAAS. The paper, by M. Wallner at Temple University in Philadelphia, PA; and colleagues was titled, "HDAC inhibition improves cardiopulmonary function in a feline model of diastolic dysfunction." view more
Credit: M. Wallner <i>et al., Science Translational Medicine</i> (2019)